一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括Valemetostat tosylate；T-DXd；Dato-DXd，当前状态为研究进行中，已停止招募。登记地点显示中国北京、广州、黑龙江省、湖南省等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Valemetostat tosylate；T-DXd；Dato-DXd · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Third Hospital · 北京
- Sun Yat-Sen University, Cancer Center · 广州
- SunYat-Sen University Cancer Center · 广州
- Harbin Medical Univeristy Cancer Hospital · 黑龙江省
- Hunan Cancer Hospital · 湖南省
- Jilin Cancer Hospital · 吉林市
- Jinana Center Hosptial · 山东省
公开的入选条件
- All participants must meet all of the following criteria, as well as all criteria from the relevant sub-protocol to be eligible for enrollment:
- * At least 18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form (ICF) is signed.
- * Has at least 1 measurable lesion based on investigator imaging assessment (computed tomography or magnetic resonance imaging) using RECIST v 1.1 at Screening.
- * Is willing to provide an adequate tumor sample.
- * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.
- Additional Key Inclusion for Sub-Protocol A:
- * Diagnosed with pathologically documented breast cancer that:
- 1. Is unresectable or metastatic.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06244485；登记信息更新于 2026-09-15。